Corporate ActionAug 5, 2026, 10:35 PM
Braveheart Bio Prices Upsized IPO of 21.25M Shares at $18.00, Raising $382.5M
AI Summary
Braveheart Bio, Inc. announced the pricing of its upsized initial public offering, offering 21,250,000 shares of common stock at $18.00 per share. This offering is expected to generate gross proceeds of $382.5 million. The shares are anticipated to begin trading on the Nasdaq Global Market under the ticker "BRVE" on August 6, 2026, with the offering expected to close on August 7, 2026. The underwriters also have an option to purchase additional shares.
Key Highlights
- Braveheart Bio priced its upsized initial public offering of 21,250,000 shares of common stock.
- The shares were priced at $18.00 per share.
- The gross proceeds from the IPO are expected to be $382.5 million, before deductions.
- Shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026, under the ticker "BRVE".
- Underwriters have a 30-day option to purchase up to an additional 3,187,500 shares.
- The offering is expected to close on August 7, 2026.
Price Impact
More from BRVE